×

Biotech and Pharmaceuticals Medicine

  • Texas officials: Patient's symptoms began days after US return

    CNBC's Meg Tirrell reports Texas health officials have confirmed the Ebola patient is in Texas, and had a recent history of travel to West Africa.

  • The Centers for Disease Control sign is seen at its main facility in Atlanta, Georgia.

    Shares of pharmaceutical companies working on a drug to treat Ebola spiked after the CDC confirmed the first case diagnosed in the U.S.

  • Pharma companies spike ahead of CDC newser

    The CDC has confirmed the first Ebola case diagnosed in the U.S. The "Fast Money" traders discuss the companies spiking on the news.

  • First Ebola case diagnosed in US confirmed

    The CDC has confirmed the first Ebola case diagnosed in the U.S. and will hold a news conference at 5:30PM E.T. Tuesday. CNBC's Meg Tirrell has the details.

  • CDC confirms first Ebola case in US

    The CDC will hold a news conference on a U.S. Ebola case at 5:30PM E.T., reports CNBC's Dominic Chu.

  • Joe Namath tackles head injuries

    Former NFL quarterback Joe Namath is taking on the fight against debilitating effects of brain injuries.

  • Positive data from Roche breast cancer drug

    A breast cancer drug from Roche known as Perjeta helped patients live nearly 16 months longer compared with Herceptin and chemotherapy alone. CNBC's Meg Tirrell provides insight to the data.

  • Medicins Sans Frontieres health workers at an isolation camp in Liberia during the visit of the UN Ebola systems coordinator, Aug. 23, 2014.

    The World Bank on Thursday announced it would give another $170 million to help West African countries contain the spread of the Ebola virus.

  • New Ebola estimate

    CNBC's Meg Tirell reports the latest projections on the Ebola virus.

  • The world's attention may have shifted to U.S. airstrikes on Syria, but West Africa continues to be ravaged by the worst outbreak of Ebola.

  • Pharma in focus: Ebola & Enterovirus D68

    CNBC's Meg Tirrell runs down today's top health care headlines, including a major move by President Obama to fight the Ebola virus and the latest on Enterovirus D68.

  • Accelerating Ebola vaccine

    CNBC's Meg Tirrell speaks to Johnson & Johnson chairman, Joaquin Duato, about J&J's partnership with the National Institutes of Health to fast track its Ebola vaccine program to begin human testing by early 2015.

  • Diabetes monitoring goes mobile

    Discussing the new ways to monitor glucose for people with diabetes, and competition in the space, with Terry Gregg, DexCom CEO. Gregg says his business is in conversations with Apple and Samsung in regards to partnering on wearables.

  • Biotech's $10 billion opportunity

    CNBC's Meg Tirrell reports experimental cholesterol medicines by Amgen and Regeneron represent a potential $10 billion opportunity pending FDA approval in the U.S.

  • Race for cholesterol drugs

    A new class of drugs which aim to lower levels of LDL are being pursued by multiple pharma companies and it could be a $10 billion market. Leonard Schleifer, Regeneron CEO, discusses what is known about bad cholesterol, and competition in the space.

  • Ebola response roadmap

    GlaxoSmithKline is to begin human testing of an experimental Ebola vaccine. CNBC's Meg Tirrell reports the World Health Organization has released a response roadmap with the goal of stopping the spread of Ebola in 6 to 9 months.

  • Medicins Sans Frontieres health workers at an isolation camp in Liberia during the visit of the UN Ebola systems coordinator, Aug. 23, 2014.

    The trials will start at the NIH in Maryland. A vaccine is "the first step in a long process" to control Ebola, Dr. Anthony Fauci says. NBC reports.

  • A pharmacist searches for drugs in a pharmacy in Lagos, Nigeria, July, 2014.

    Nigeria's health minister has insisted the Ebola outbreak has been contained in the country.

  • Roche's blockbuster pharma deal

    CNBC's Meg Tirrell breaks down the mega deal between Swiss pharmaceutical firm Roche and InterMune for $8.3 billion.

  • Roche CEO: InterMune perfect strategic fit

    CNBC's Meg Tirrell speaks to Roche CEO Severin Schwan, and InterMune CEO Daniel Welch, about Roche's $8.3 billion acquisition of InterMune and the opportunity for the drug Esbriet in the U.S.